

Title	Vitamin D in pregnancy: Where we are and where we should go
Authors	Kiely, Mairead E.;Wagner, C. L.;Roth, D. E.
Publication date	2020-04-14
Original Citation	Kiely, M. E., Wagner, C. L. and Roth, D. E. (2020) 'Vitamin D in pregnancy: Where we are and where we should go', Journal of Steroid Biochemistry and Molecular Biology, 201, 105669 (9pp). doi: 10.1016/j.jsbmb.2020.105669
Type of publication	Article (peer-reviewed)
Link to publisher's version	10.1016/j.jsbmb.2020.105669
Rights	© 2019, Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC BY-NC-ND 4.0 license https:// creativecommons.org/licenses/by-nc-nd/4.0/
Download date	2024-06-18 13:37:19
Item downloaded from	https://hdl.handle.net/10468/10311



University College Cork, Ireland Coláiste na hOllscoile Corcaigh

Manuscript Details

Manuscript number	SBMB_2019_585_R1
Title	Vitamin D in pregnancy: Where we are and where we should go
Article type	Review Article

Abstract

Vitamin D deficiency has been widely reported among pregnant women and infants around the world. Women with low sun exposure, high BMI, low vitamin D intakes and socioeconomic disadvantage with poor guality diets are at greatest risk of vitamin D deficiency, leading to very low serum concentrations of 25-hydroxyvitamin D (25(OH)D) in their offspring and an increased risk of nutritional rickets. Many observational studies, supported by compelling in vitro and in vivo data, have generated evidence suggesting that low vitamin D status in pregnancy may also contribute to the risk of adverse perinatal outcomes including hypertensive disorders (e.g., preeclampsia), fetal growth restriction, and preterm birth. However, the few large randomized controlled trials (RCTs) conducted to date have generated conflicting evidence for a role of vitamin D supplementation in improving perinatal outcomes. Vitamin D supplementation policies during pregnancy and implementation of policies vary within and between jurisdictions. Regulatory authorities have cited insufficient evidence to establish pregnancy-specific targets for serum 25(OH)D concentrations or prenatal vitamin D intake that effectively reduce the risks of adverse perinatal and infant outcomes. This paper arises from a Debate on Vitamin D Requirements during Pregnancy, held at the 22nd Vitamin D Workshop, 2019. From varied perspectives, our objectives were to evaluate the evidence for: vitamin D metabolism in pregnancy and the prevalence of gestational vitamin D deficiency worldwide; the translation of laboratory research findings to clinical studies on the role of vitamin D in perinatal health; the challenges of designing and conducting clinical trials to establish prenatal vitamin D requirements; and results to date of major large RCTs of prenatal vitamin D supplementation. Lastly, we explored potential next steps towards generating robust clinical data in this field to address both public health protection and patient care.

Keywords	Vitamin D; Vitamin D Requirements; Pregnancy; Perinatal health; Vitamin D status
Corresponding Author	Mairead E. Kiely
Corresponding Author's Institution	University College Cork
Order of Authors	Mairead E. Kiely, Carol Wagner, Daniel Roth
Suggested reviewers	Martin Hewison, James Fleet

Submission Files Included in this PDF

File Name [File Type]

Response to Reviewers Comments_03 13 20.docx [Response to Reviewers]

HIghlights.docx [Highlights]

Controversies in Vitamin D Revised Final Clean.docx [Manuscript File]

To view all the submission files, including those not included in the PDF, click on the manuscript title on your EVISE Homepage, then click 'Download zip file'.

Controversies in Vitamin D

Vitamin D in pregnancy: Where we are and where we should go

M.E. Kiely ^{1,2}, C.L. Wagner ³, D.E. Roth ⁴

¹ Cork Centre for Vitamin D and Nutrition Research, School of Food and Nutritional Sciences, University College Cork, Ireland, ² INFANT Research Centre, University College Cork, Ireland, ³ Division of Neonatology, Medical University of South Carolina, Charleston, SC 29425, United States, ⁴ Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.

Abstract

Vitamin D deficiency has been widely reported among pregnant women and infants around the world. Women with low sun exposure, high BMI, low vitamin D intakes and socioeconomic disadvantage with poor quality diets are at greatest risk of vitamin D deficiency, leading to very low serum concentrations of 25-hydroxyvitamin D (25(OH)D) in their offspring and an increased risk of nutritional rickets. Many observational studies, supported by compelling *in vitro* and *in vivo* data, have generated evidence suggesting that low vitamin D status in pregnancy may also contribute to the risk of adverse perinatal outcomes including hypertensive disorders (e.g., preeclampsia), fetal growth restriction, and preterm birth. However, the few large randomized controlled trials (RCTs) conducted to date have generated conflicting evidence for a role of vitamin D supplementation in improving perinatal outcomes. Vitamin D supplementation policies during pregnancy and implementation of policies vary within and between jurisdictions. Regulatory authorities have cited insufficient evidence to establish pregnancy-specific targets for serum 25(OH)D concentrations or prenatal vitamin D intake that effectively reduce the risks of adverse perinatal and infant outcomes. This paper arises from a Debate on Vitamin D Requirements during Pregnancy, held at the 22nd Vitamin D Workshop, 2019. From varied perspectives, our objectives were to evaluate the evidence for: vitamin D metabolism in pregnancy and the prevalence of gestational vitamin D deficiency worldwide; the translation of laboratory research findings to clinical studies on the role of vitamin D in perinatal health; the challenges of designing and conducting clinical trials to establish prenatal vitamin D requirements; and results to date of major large RCTs of prenatal vitamin D supplementation. Lastly, we explored potential next steps towards generating robust clinical data in this field to address both public health protection and patient care.

Key-words: Vitamin D; Vitamin D Requirements; Pregnancy; Perinatal health; Vitamin D status

1 Introduction

- 2 Pregnancy and infancy are life-stages for which evidence of low vitamin D status is
- 3 widespread but the evidence basis for setting dietary requirements for vitamin D is weakest
- 4 (Institute of Medicine, 2011). Prevention of low vitamin D status is required to reduce the
- 5 risk of nutritional rickets among children and adolescents and osteomalacia in adults, which
- 6 can have severe and lasting consequences for bone growth and skeletal integrity (Munns et al
- 7 2016). The recent discovery of non-skeletal roles for vitamin D has changed the landscape
- 8 considerably and mechanistic studies have elaborated the molecular roles of vitamin D in
- 9 many systems, for example, immunity (Adams and Hewison, 2008, Chun et al., 2014b).
- 10 Modulation of the intrauterine immune environment by vitamin D has been implicated in
- 11 adverse perinatal outcomes, including recurrent pregnancy loss, preeclampsia and
- 12 spontaneous preterm birth (Liu and Hewison, 2012, Tamblyn et al., 2015). Indications are
- 13 that early pregnancy may be the critical window for prevention of these adverse events.
- 14 The definition of healthy vitamin D status during pregnancy, typically indicated by
- 15 circulating concentrations of 25-hydroxyvitamin D (25(OH)D), is the subject of intense
- 16 debate, which has been challenged by a lack of data from well-powered, well-controlled trials
- 17 in pregnant women, particularly among women with low circulating 25(OH)D at baseline.
- 18 Multiple systematic reviews of the role of vitamin D supplementation during pregnancy have
- 19 been published but these have lacked data from substantial trials and there is no consensus as
- 20 to whether physiological requirements for 25(OH)D are higher during pregnancy than in non-
- 21 pregnant adults (Roth et al., 2017). It is also worth noting that trials and reviews of trials have
- 22 framed the question around the benefit of *additional* vitamin D supplementation during
- 23 pregnancy (using a pharmacological model of intervention regardless of baseline status)
- 24 rather than the role of *sufficient vitamin D to support healthy pregnancy from the outset*.
- 25 A Debate on the controversial topic of Vitamin D Requirements during Pregnancy was held
- at the 22nd Vitamin D Workshop, 2019. Our objectives were to evaluate the current state of
 the evidence for:
- vitamin D metabolism in pregnancy, and the prevalence of gestational vitamin D
 deficiency worldwide;
- the translation of laboratory research findings to clinical studies on the role of vitamin
 D in perinatal health;
- the challenges of designing and conducting clinical trials to establish prenatal vitamin
 D requirements; and,
- results to date of major large RCTs of prenatal vitamin D supplementation.
- The three authors hold some shared and some divergent views on the core issues discussed and provided their perspectives on these issues. Our common goal was to explore potential next steps towards generating robust clinical data in this field to address both public health protection and patient care. In the presentation of the evidence in this paper, we aimed to convey the plurality of divergent viewpoints rather than present a unified or consensus statement.

41 Low vitamin D status is common among pregnant women and infants

- 42 A key question to be addressed is whether the prevalence of $25(OH)D \le 25-30$ and ≤ 50
- 43 nmol/L is higher among pregnant women than among other population groups. Saraf and
- 44 colleagues (2016) estimated the global prevalence of 25(OH)D concentrations < 50 nmol/L at
- 45 54% among pregnant women and 75% among newborns. Almost one in five pregnant women
- and one in three newborns were below 25 nmol/L, placing them at increased risk of
- 47 developing rickets and osteomalacia. A systematic review of 25(OH)D concentrations in low-
- 48 and middle-income countries (LMIC) by Cashman et al (2019) reported that 29 out of the 83
- countries included had 25(OH)D data available. Afghanistan, Pakistan, India, Tunisia, Syria,
 the West Bank and Gaza and Mongolia were classified as "hot spots" for very low 25(OH)D
- 51 (<25-30 nmol/L) among women, pregnant women or infants on the basis of having a
- 52 prevalence in excess of 20%(Cashman et al., 2019). In low income and middle eastern
- 53 countries in particular, women and girls appear to have lower circulating 25(OH)D than their
- 54 male counterparts, probably due to clothing practices (Roth et al., 2018a, Lips et al., 2019).
- 55 Palacios and Gonzales (2014) described a high prevalence (>20%) of 25(OH)D <30 nmol/L
- 56 among pregnant women and infants, in many countries, including in South Asia and the
- 57 Middle East; up to 60% of women in India and 86% of infants in Iran had 25(OH)D < 30
- 58 nmol/L.
- 59 One of the challenges of interpreting global 25(OH)D data is the methodological variability
- 60 in analytical methods and data reporting, which can be particularly challenging for maternal
- 61 samples (Best et al 2019). The relatively low uptake, and low rate reporting of laboratory
- 62 performance of users of quality assurance systems, such as DEQAS (Carter et al 2017), leads
- 63 to a lack of transparency. Application of the NIH Vitamin D Standardization Protocol
- 64 (VDSP) should be used to standardize 25(OH)D data if serum aliquots are available for re-
- analysis by LC-MS/MS, using a validated statistical approach (Durazo-Arvizu et al 2017).
- 66 The CDC Vitamin D Standardization-Certification Program (VDSCP) is also available as an
- 67 avenue to achieve accreditation of 25(OH)D analysis.
- 68 Within temperate countries, the prevalence of vitamin D deficiency is much higher among
- 69 persons with darkly pigmented skin tones. Using VDSP, the ODIN project reported the first
- 70 internationally standardised dataset of vitamin D status and the prevalence of vitamin D
- 71 deficiency across Europe (Cashman et al., 2016). While the overall prevalence of 25(OH)D <
- 72 30 nmol/L was 13%, about twice that of the US (5.9%) (Schleicher et al., 2016) and Canada
- 73 (7.4%) (Sarafin et al., 2015), persons with more darkly pigmented skin tones were at much
- ⁷⁴ higher risk than their white counterparts both in Europe and North America. As part of the
- 75 ODIN project, Kiely et al. (2016) analysed a pregnancy cohort of 1800 women in Ireland,
- 76 where there is no maternal vitamin D supplementation policy. Data from CDC-accredited
- 77 LC/MS-MS analysis of 25(OH)D showed that 17% were below 30 nmol/L at 15 weeks of
- 78 gestation; this was 49% among women of ethnic minority (Kiely et al., 2016). Among the
- infants of this cohort, 46% of umbilical cord sera had a 25(OH)D < 30 nmol/L; this was 73%
- 80 among infants from women of ethnic minority (Kiely et al., 2017b).
- 81 Nutritional Rickets

- 82 In line with the prevalence data for 25(OH)D among mothers and newborns, it is no surprise
- to note that the greatest burden of nutritional rickets is in Africa, Asia and the Middle East
- 84 (Thacher et al., 2006, Prentice, 2013). There is also evidence that while the incidence of
- 85 nutritional rickets is stable or decreasing among whites, it is increasing in North America and
- 86 Europe among immigrant populations (Creo et al., 2017). Thacher et al (2016) provided a
- summary of nutritional rickets in immigrant and refugee children using data collected in the
 UK, Denmark, Australia, Canada and the US. Populations most at risk were South Asian,
- African and Middle Eastern African, with incidence rates (per 1000,000/year) up to 24 in
- 90 young children < 3 years and up to 4.9 among children <15 years. The stark contrast between
- 91 whites and ethnic minorities in western countries is highlighted in the *Global Consensus*
- 92 *Recommendations on Prevention and Management of Nutritional Rickets* (Munns et al.,
- 93 2016). Most clinical insights are gained from hospital admissions; Uday et al (2018) have
- 94 documented hypocalcemic dilated cardiomyopathy associated with nutritional rickets and in
- 95 some cases, fatal consequences. These prevalence estimates of maternal and infant 25(OH)D
- 96 concentrations and the resulting effects elevate vitamin D deficiency among mothers and
- babies to the status of a serious public health problem that requires urgent action.
- 98

99 Challenges in defining nutritional requirements for vitamin D during pregnancy

- 100 To provide the policy context, Mairead Kiely (MK) also summarized current dietary
- 101 recommendations for vitamin D in in pregnant and lactating women in line with the 25(OH)D
- 102 concentration targets they are intended to reach. Individual intake recommendations range
- 103 from 5 to 15 μ g/day (200-600 IU) to achieve 25(OH)D targets of \geq 25 to 50 nmol/L (10 to 20
- 104 ng/mL) (Kiely et al., 2017a). Although there is some variation between these
- 105 recommendations, they were all formulated based on evidence from RCTs of vitamin D
- 106 status and bone health outcomes. Due to a lack of evidence on which to set nutritional
- 107 requirements for 25(OH)D during pregnancy specifically, recommendations for vitamin D
- 108 intake are the same for pregnant and lactating women as non-pregnant adults.
- 109 Vitamin D requirements from the perspective of vitamin D biology
- 110 Carol Wagner (CW) presented data showing that unlike other times during the lifespan,
- 111 pregnancy involves the orchestration of events that must protect the mother while allowing
- 112 growth and development of the fetus. There is a delicate immune balance that nurtures the
- allogeneic fetus, while maintaining reactivity against pathogens to the outside world (Racicot
- et al., 2014, Mor and Cardenas, 2010, Vijayendra Chary et al., 2015a). During the first
- 115 trimester, a proinflammatory state allows for the invasion of the uterine wall by fetal derived
- 116 cytotrophoblast cells to become the placenta. Following the establishment of the maternal-
- 117 placental-embryonic unit, there is rapid growth of the fetus, which must occur in a state that
- is by comparison to the earlier first stage of pregnancy, anti-inflammatory (Racicot et al.,
- 119 2014, Mor and Cardenas, 2010). This relatively anti-inflammatory state will last well beyond
- 120 the second trimester and into the third trimester, when the uterine environment becomes more
- 121 proinflammatory to allow the onset of labour and the expulsion of the fetus from the uterus
- 122 (Racicot et al., 2014, Mor and Cardenas, 2010). Dysregulation of these tightly controlled

- 123 biophenomena at a systemic and placental level have been considered as a
- 124 potential mechanism mediating pathogenesis of recurrent pregnancy loss (Ji et al., 2019)
- 125 preeclampsia and spontaneous preterm birth (Weiss et al., 2016, Mirzakhani et al., 2016). It is
- 126 postulated by many that these adverse events during pregnancy have their origins early-on in
- 127 pregnancy, with derangement of the critical balance in immune function (Hollis and Wagner,
- 128 2017b, Liu and Hewison, 2012, Tamblyn et al., 2015).

129 1,25(OH)₂D mediates gene expression via VDR and VDREs, and increased concentrations of 130 1,25(OH)₂D could have implication for gene pathways and subsequent function. In mouse 131 models of vitamin D deficiency studied early in gestation, an array of genes in the placenta are 132 upregulated and others downregulated based on maternal vitamin D status (Liu et al., 2011), which find corollaries in human studies, especially following adverse pregnancy outcomes 133 134 such as preeclampsia (Powe et al., 2010, Robinson et al., 2010, Baker et al., 2010, Bodnar et 135 al., 2014, Mirzakhani et al., 2016). Parallel findings are noted in the upregulation of certain 136 placental genes that have been implicated in preeclampsia (Schulz et al., 2017). There are 137 studies that describe alternation in T cell phenotype associated with preterm birth (Zahran et 138 al., 2018) and recurrent pregnancy loss in women who are vitamin D deficient (Ji et al., 2019, 139 Kwak-Kim et al., 2016, Wu et al., 2018, Sharif et al., 2018). There are also non-genomic 140 calcitriol-dependent biological effects that can take place in cells, involving second messengers

- generated by membrane-initiated signalling pathways (Novakovic et al., 2009).
 Classic vitamin D receptor (VDR) and the membrane-associated rapid response steroid-
- binding protein (MARRS) found in the cell membrane may bind 1,25(OH)₂D and initiate the
- 144 activation of numerous pathways involving various protein kinases (PKC), MAPK, PKA,
- 145 phosphatidyl inositol phosphate, and Ca2+ and chloride channels (Olmos-Ortiz et al., 2015).
- 146 The VDR and regulatory metabolic enzymes are expressed in both placenta and decidua,
- 147 indicating a potential critical point in the immunomodulation at the maternal-fetal interface
- 148 (Vijayendra Chary et al., 2015b). Further, activities of vitamin D response element (VDRE)-
- 149 containing genes can be grouped in quite diverse biological networks: bone and mineral
- 150 metabolism; cell life and death (comprising proliferation, differentiation and apoptosis);
- 151 immune function—both innate and adaptive immunity that are thought to be operational
- 152 during the various stages of pregnancy (Knabl et al., 2017).
- 153 During pregnancy, there are major adaptations in vitamin D metabolism. After conception,
- 154 the fertilized egg undergoes a series of reproductive cell divisions to form the three germ
- 155 layers—endoderm, mesoderm, and ectoderm) that give rise to different types of cells, many
- 156 of which express the vitamin D receptor (VDR) (Kaludjerovic and Vieth, 2010). Various
- 157 cells give rise to different organs through organogenesis that extends from 4 to 10 weeks of
- 158 gestation with the placental fully formed and functional by 4 weeks of gestation. During this
- 159 time of immense activity and growth, localized concentrations of vitamin D in the form of
- 160 25(OH)D (which crosses the placenta from the maternal side) and $1,25(OH)_2D$ (which is
- 161 synthesized by the fetus as early as 6-10 weeks of gestation) can interact with various
- 162 signalling systems to regulate organ development (Kaludjerovic and Vieth, 2010). As
- 163 mentioned, it is the placenta that permits the transfer of 25(OH)D from the mother to the
- 164 fetus but also the placenta through its production of 1α -hydroxylase that local synthesis of
- 165 1,25(OH)₂D occurs. 1,25(OH)₂D binds to VDR in specialized cells to induce genomic and
- 166 nongenomic responses that stimulate organ development.

- 167 Focusing on 1,25(OH)₂D during pregnancy, 1,25(OH)₂D increases more than 2–3 fold in the
- 168 first weeks of pregnancy that appears to come mainly from maternal kidney synthesis but
- some is placentally-derived (Bikle et al., 1984, Hollis et al., 2011, Tamblyn et al., 2018, Best
- 170 et al., 2019). This increase is noted in both animal models and human studies as measured by
- 171 RIA and LC-Tandem mass spec (LC-MS) and is accompanied by a rise in VDBP, the main
- 172 carrier of all vitamin D moieties with greater avidity for 25(OH)D (Bikle et al., 1984,
- 173 Vijayendra Chary et al., 2015a, Hollis et al., 2011)(Hollis and Wagner, 2017a, Novakovic et
- al., 2009, Best et al., 2019). Despite this, there is no corresponding rise in 25(OH)D during
- 175 pregnancy (Hollis and Wagner, 2017a).
- 176 The increase in 1,25(OH)₂D early in the first trimester of pregnancy is linked to higher
- 177 Cyp27B1 (1-α-hydroxylase) activity in maternal kidney, placental trophoblasts and decidua
- 178 (Bikle et al., 1984, Olmos-Ortiz et al., 2015, Whitehead et al., 1981, Hollis et al., 2011).
- 179 Longitudinal human studies also report a progressive increase in both bound and free
- 180 1,25(OH)₂D concentrations (Best et al., 2019). Previous animal studies in partly and
- 181 completely nephrectomized rats report that this rise is mainly attributed to increased maternal
- 182 synthesis *per se*, rather than decreased clearance (Gray et al., 1979). This increase in
- 183 1,25(OH)₂D occurs at a time during pregnancy before increased fetal calcium requirements
- 184 manifest, increasing from ~2 mg/day in the first trimester to 100 mg/day in last trimester that
- 185 is continued throughout lactation. Yet, immediately after delivery, maternal calcitriol
- 186 concentrations return to pre-pregnancy levels, despite significant calcium requirements
- 187 needed during lactation (Carneiro et al., 2010, Ritchie et al., 1998). 1,25(OH)₂D
- 188 concentrations by 12 weeks of gestation have already increased to a mean of 180 pmol/L,
- 189 further increasing to around 300 pmol/L toward the end of pregnancy, compared to
- 190 nonpregnant control mean concentration of 91 pmol/L (Papapetrou, 2010, Ardawi et al.,
- 191 1997, Hollis et al., 2011). Calcitriol circulates at low levels in fetal blood, typically less than
- 192 50% of the maternal value (Fleischman et al., 1980, Hollis and Pittard, 1984a, Seki et al.,
- 193 1994, Hillman et al., 1985). Both animal models and human data suggest that 25(OH)D
- readily crosses the placenta, with cord blood concentrations that are around 70-100% of maternal concentrations (Hallis and Dittard 1084a, Hallis et al. 2011, Best et al. 2010)
- maternal concentrations (Hollis and Pittard, 1984a, Hollis et al., 2011, Best et al., 2019).
 Calcitriol synthesis in the fetus is likely suppressed by the high serum calcium, high
- 197 phosphorus, and low PTH concentrations typically observed in cord blood (Kovacs, 2014).
- 198 It is interesting that the rise in maternal 1,25(OH)₂D during pregnancy occurs without any 199 effect on serum ionized or corrected calcium and appears to result from uncoupling of 200 1,25(OH)₂D from its well-established actions in the non-pregnant state (Hollis et al., 2011). 201 While VDBP increases concomitantly, it does not increase to the same degree as 1,25(OH)₂D 202 (Hollis et al., 2011). In addition, upregulation of CYP27B1 mRNA in the maternal kidneys, 203 exerts characteristics of "extrarenal" production from an endocrine standpoint, such as 204 relative unresponsiveness to stimulation by PTH (except under conditions of extreme vitamin 205 D deficiency) and lack of feedback inhibition of CYP27B1, and thus, 1-α-hydroxylase by 206 1,25(OH)₂D itself. This increase in 1,25(OH)₂D seems to be independent of parathyroid 207 hormone (PTH), which itself remains within the normal adult range throughout pregnancy 208 (Wagner and Hollis, 2011, Haddow et al., 2011, Hollis et al., 2011). Other hormones could

- 209 also contribute to the bioregulation of $1-\alpha$ -hydroxylase such as PTH-rP, estradiol, prolactin, 210 and placental lactogen (Ardawi et al., 1997).
- As shown in **Figure 1** below (from Hollis et al, with permission, (Hollis et al., 2011), this
- 212 kinetic reaction saturation graph of 25(OH)D and 1,25(OH)₂D shows that 25(OH)D has
- 213 direct influence on 1,25(OH)₂D concentrations throughout pregnancy, an event which does
- not occur during any other time during human life. It is apparent in the figure that as lower
- 215 concentrations of $1,25(OH)_2D$ increase, first order kinetics becomes zero order kinetics, with
- a plateauing of the graph and an inflection point at 100 nmol/L (40 ng/mL) 25(OH)D—the
- 217 level required to optimize 1,25(OH)₂D production during pregnancy. (**Place Figure 1 near**
- 218 here)
- 219 Based on these findings, it is thought by some that this inflection point of 100 nmol/L may be
- critical during pregnancy for both maternal and fetal well-being, and that attainment of this
- threshold early-on may be key. There are data to suggest that vitamin D status early in
- 222 pregnancy sets the stage for vitamin D's enabling effect on immune function (Mirzakhani et
- al., 2016, Weiss and Litonjua, 2017). In their *post hoc* analysis using multivariable log-
- binomial regression of maternal 25(OH)D status during pregnancy, McDonnell et al reported
- 225 that women attaining maternal 25(OH)D concentrations \geq 100 nmol/L compared to \leq 50
- nmol/L, adjusted for covariates, was associated with a reduction in the risk of preterm birth
- 227 by 59% (McDonnell et al., 2017).
- 228 With more modern scientific technological advancement, vitamin D has been shown to act on 229 innate and structural cells to promote antimicrobial defense through induction of antimicrobial 230 peptides (e.g. cathelicidin, beta-defensins) and autophagy (Liu et al., 2006, Chun et al., 2014a). 231 Bridging both innate and adaptive immunity, vitamin D also acts on myeloid dendritic cells 232 (DC) to promote a tolerogenic antigen presenting cell (APC) phenotype (Penna et al., 2007). 233 In their recent review, Hawrylowicz and Santos provide compelling evidence that vitamin D 234 reduces naïve T cell expansion, and downregulates Th1 and Th17 responses, but has variable 235 effects on Th2 responses linked to allergic disease (Hawrylowicz and Santos, 2019). These 236 interactions result in an increased frequency of human Foxp3 and IL-10 Treg in vitro and in 237 vivo (Penna et al., 2005, Van Der Aar et al., 2011, Nikolic and Roep, 2013, Urry et al., 2012, 238 Pfeffer and Hawrylowicz, 2018, Hawrylowicz and Santos, 2019, Jeffery et al., 2009). 239 Similarly, Vasiliou et al., in their human dust mite-allergy mouse model, showed that vitamin 240 D deficiency *in utero* led to an increased frequency of Th2 cells and reduced anti-inflammatory IL-10+ T cells in the lungs (Vasiliou et al., 2014), arguing for an *in utero* process that continues 241 242 after birth. As noted by Hawrylowicz and Santos (Hawrylowicz and Santos, 2019), neonatal 243 and adult immunity differs, and assumptions of how vitamin D promotes protective immunity 244 in pregnancy and neonates may be distinct to effects in adults, as they note that in recently 245 published, independent vitamin D supplementation pregnancy studies that showed such 246 differences (e.g. no correlation with Foxp3) (Hornsby et al., 2018, Chi et al., 2011, Guven et 247 al., 2012). Clearly, more research is needed in this area to inform the design of more meaningful 248 clinical trials.
- 249
- 250 Translation of laboratory findings to clinical studies

251 Palacios (2019b) concluded that notwithstanding inconsistent reporting of adverse events, 252 vitamin D supplementation appears safe. Studies presented by CW also showed a high degree 253 of safety in both mother and fetus/neonate and later, in the offspring during longitudinal 254 follow-up studies (Hollis et al., 2011, Wagner et al., 2013b, Wagner et al., 2013a, Al-Garawi 255 et al., 2016, Chawes et al., 2016, Zhang et al., 2016, Litonjua et al., 2016, Wolsk et al., 256 2017b, Roth et al., 2018b, Hornsby et al., 2018, Stukes et al., 2016, Kelly et al., 2019, Litonjua et al., 2020). During pregnancy, there was no evidence of toxicity from high 257 258 25(OH)D concentrations or differences in maternal serum calcium, phosphorus, and urinary 259 calcium/creatinine ratios or adverse pregnancy outcomes among the many women who have 260 been supplemented with various combinations of vitamin D up to 110 µg/day or 1250 261 µg/week during pregnancy. There are some individuals, however, who could develop 262 toxicity if not previously diagnosed with idiopathic hypercalcemia of childhood associated with Williams Syndrome (a rare genetic disorder that results in hypercalcemia with even 263 modest vitamin D supplementation due to abnormal metabolic processing (Aravena et al., 264 265 2002) or from other metabolic genetic defects in vitamin D processing such as CYP24A1 266 mutations (Macdonald et al., 2020). Some studies show benefit to the pregnant woman and her developing fetus with improved vitamin D status (Rostami et al., 2018) vet others do not 267 (Roth et al., 2018b), but none have shown toxicity with higher dosing within certain inclusion 268 269 and exclusion entry criteria. Despite the known basic science aspects of vitamin D, clinical 270 trials often fail to note differences in outcomes of supplementation during pregnancy due to a

271 number of factors listed in **Table 1 (place Table 1 near here)**.

272 Based on animal and clinical studies looking at the effect of vitamin D status at baseline early 273 in pregnancy and pregnancy outcomes (Liu et al., 2013, Dawodu et al., 2013, Chan et al., 274 2015, Mirzakhani et al., 2016, Hewison, 2018), it would appear that the most profound 275 effects of early supplementation are seen in those with the greatest deficiency states at 276 baseline (Ganguly et al., 2018, Rostami et al., 2018). In addition, it would appear that the 277 effects are seen more notably when total circulating 25(OH)D is used as the biomarker of 278 vitamin D status during pregnancy rather than analysed on an intention-to-treat (ITT) basis. 279 Higher dose effects are more apparent in those who follow the prescribed supplementation 280 regimen and when the analysis is on a *per* protocol basis (Abercrombie et al., 2018). Another consideration is that in a classic drug study with ITT analysis, the concentration of the drug in 281 282 question starts at 0 in both the control and treatment group(s); yet, in nutrient studies such as 283 vitamin D supplementation trials, no one starts at a concentration of zero. For this reason, 284 Heaney outlined the criteria that should be met for all nutrient studies to avoid this faulty 285 design (Heaney, 2014). The other question that continues to plague vitamin D studies is what 286 is really representative of that nutrient—in this case, vitamin D? Is it the parent compound or 287 a metabolite—25(OH)D, and is that metabolite really indicative of what is going on at the 288 cellular level? Should the metabolite be measured in its bound form or its free state 289 (Tsuprykov et al., 2019, Best et al., 2019)?

290 Best et al provide a longitudinal examination of the changes in various moieties of vitamin D

during adolescent pregnancy and included in their analyses free circulating 25(OH)D

292 measurement as well as VDBP (Best et al., 2019). In their analysis of 58 adolescent pregnant

- 293 females, the authors found that regardless of race or visit, total 25(OH)D was a stronger
- correlate of PTH, 1,25(OH)₂D, and of the catabolite 24,25(OH)₂D than free circulating
- 295 25(OH)D, and neither total nor free 25(OH)D was related to serum calcium. While African
- American pregnant girls had lower total 25(OH)D (p < 0.0001), their free 25(OH)D did not
- significantly differ by race (p = 0.2). Of interest, in these pregnant adolescents, VDBP
- 298 concentration was elevated and inversely associated with the percent free 25(OH)D, but
- 299 measured free 25(OH)D provided no advantage over total 25(OH)D as a predictor of PTH,
- 300 1,25(OH)2D, 24,25(OH)2D, or calcium. Thus, it appears for the moment that total circulating
- 301 25(OH)D concentration is the best indicator of vitamin D status.
- 302 Other issues in assessing vitamin D status during pregnancy and its relevance to outcomes
- 303 includes the question of whether baseline 25(OH)D in a study represents the 25(OH)D
- 304 concentration circulating around the time of conception. Vitamin D supplementation as a
- treatment is plagued with nonadherence whereas using 25(OH)D as the biomarker is not.
- 306 There are also issues of whether or not total circulating 25(OH)D is reflective of vitamin D
- 307 metabolism within the cell, especially with variable bolus dosing. Perhaps it is baseline
- 308 25(OH)D in early pregnancy or even preconception that is more relevant in showing the
- 309 effect of vitamin D status on the fetal and maternal health, but to date, no trials have
- addressed circulating 25(OH)D at the time of conception and placental activity.
- 311 Systematic reviews and meta-analyses of vitamin D supplementation during pregnancy show
- 312 mixed results in prevention of preeclampsia and preterm birth, which may reflect timing of
- 313 supplementation initiation as well as study design in terms of dosing regimen and maternal
- 314 vitamin D status starting point (as noted in Table 1). The differences between *in vitro* and
- animal studies results of vitamin D's role as an enabler and the often-null results of
- 316 randomized controlled trials challenges us to explore alternative hypotheses and to design
- 317 studies that integrate these divergent findings.
- 318 Another factor that could potentially affect study results includes estimation of sample size.
- 319 On what do we base the sample size of a clinical trial? Is it anticipated treatment effects such
- 320 as preeclampsia, hypertension, gestational diabetes, or changes in a particular relevant
- 321 biomarker such as T cell phenotype? Another question is when in pregnancy do you look for
- 322 effect? What biomarker is most appropriate? Should sample size be based on VDBP
- 323 genotype, specific SNPs or ethnicity, all of which affect vitamin D metabolism? These
- 324 questions impact study design but also data analysis. Such questions influence clinical study
- design and create limitations in our ability to interpret the data in a meaningful manner. As
- has been the case with the advent of scientific inquiry, the basis for what we prescribe
- 327 clinically must have a demonstrated rationale that befits the data and the laboratory, and
- 328 which can be translated to bedside practices with continued meaning and relevance. Without
- 329 study design that incorporates the nature of the system—in this case a hormonal system that
- has many functions—we will fail to see benefit and make conclusions that might be
- 331 premature or biased. Through careful understanding of cellular mechanisms that may be
- influencing its demonstrated effect and a broader systems-based approach across mother,
- 333 placenta and fetus, we will move closer to a greater understanding of the dynamic effect of
- 334 vitamin D during pregnancy on both the mother and her developing fetus.

Alternative perspective based on evidence from published RCTs of prenatal vitamin Dsupplementation

337 While acknowledging the well-justified enthusiasm for the potential benefits of improving 338 vitamin D status in the prenatal period, Dan Roth (DR) presented a summary of selected 339 high-quality RCTs showing insufficiently convincing evidence to merit widespread changes 340 to clinical practice guidelines or policy (Roth et al., 2018a). As of the end of 2019, the World Health Organization (WHO) advises that, "vitamin D supplementation is not recommended 341 342 for pregnant women to improve maternal and perinatal outcomes" (World Health 343 Organization, 2016). While there is little doubt that prenatal vitamin D supplementation 344 improves maternal and fetal vitamin D status in a dose-dependent manner, the clinical 345 benefits to the mother and baby remain a subject of debate (Palacios et al., 2019b, Roth et al., 346 2017, Palacios et al., 2019a). The question is whether additional vitamin D during 347 pregnancy, over and above that required by a non-pregnant woman, is required. To illustrate 348 how prenatal vitamin D RCTs have so far failed to provide robust evidence of clinical benefits, it is instructive to consider five published blinded RCTs that each included at least 349 350 500 enrolled women, were generally of high-quality, and for which publication in reputable 351 journals suggests they underwent thorough peer review (Table 2) Place Table 2 near here. 352 None of these five trials individually demonstrated a beneficial effect of the vitamin D 353 intervention on their primary outcomes, as reported in the original trial publications (Table 354 3). For other secondary outcomes of interest (e.g., birth weight, gestational age at birth or preterm, neonatal or infant hospitalization, or gestational hypertension or preeclampsia), none 355 356 of these trials provided strong evidence of benefits of vitamin D (i.e., either the outcome was 357 reported and the effect was null or non-significant, or the outcome was not reported) (Roth et 358 al., 2018b, Litonjua et al., 2016, Cooper et al., 2016, Chawes et al., 2016, Hollis et al., 2011). 359 Importantly, these trials reported adverse event monitoring and none have raised major safety 360 concerns, so the overall inference is that prenatal vitamin D supplementation safely raises 361 25(OH)D without clearly providing other benefits to pregnant women and babies.

362 However, further efforts to unpack the results of some of these trials have led to alternative 363 interpretations based on sub-group effects, post-hoc secondary analyses, and longer-term 364 follow-up studies. For example, in their original trial report, Hollis et al. (2011) did not find 365 any significant differences in maternal and neonatal clinical outcomes (Hollis et al., 2011); 366 however, in a post-hoc analysis adjusting for race, published in 2013, Hollis and Wagner 367 wrote that, "the data from our RCT strongly suggest that vitamin D supplementation during 368 pregnancy can significantly decrease complications of pregnancy including primary caesarean section (p=0.046), hypertensive disorders of pregnancy (p=0.05) and comorbidities 369 370 of pregnancy (p=0.03)" (Hollis and Wagner, 2013). This particular interpretation of the trial 371 continues to be cited as direct evidence of the clinical benefits of high-dose prenatal vitamin 372 D supplementation (Hollis, 2019). In the primary report of the MAVIDOS trial, a planned 373 sub-group analysis indicated that vitamin D supplementation increased bone mineral content 374 in newborns delivered in the winter, in contrast to the overall null findings of the trial 375 (Cooper et al., 2016). Yet, conference presentations, press releases and news stories about 376 MAVIDOS frequently highlighted this sub-group effect and emphasized the potential 377 benefits of vitamin D (Grey and Bolland, 2016). Two of the five major trials (VDAART and

- 378 COPSAC) had similar primary outcomes related to early-childhood wheeze and asthma, and
- the pooled analysis of these trials indicated that vitamin D significantly reduced the incidence
- of asthma or recurrent wheeze in the offspring up to three years of age (Wolsk et al., 2017a).
- 381 However, follow-up of the children in one of the trials showed no sustained effects, such that
- the prevalence of asthma diagnoses by age 6 years was similar between the vitamin D and
- 383 control groups (Brustad et al., 2019).

384 Researchers and practitioners who conduct and interpret vitamin D RCTs are faced with a 385 dilemma when the primary results of a trial conflict with – or are less convincing than – other 386 *post-hoc* or alternative analyses of the same data, especially if the latter analyses support their 387 original hypothesis. Retaining the original randomized design, including all participants in 388 the analyses, and applying an intent-to-treat approach are all strategies that serve to reduce 389 biases, but there is often an appeal to dissect the data in other ways that are believed to reveal 390 hidden truths about physiology that may be obscured by the bluntness of the RCT approach 391 (Figure 2). Conventional analysis of a RCT is by no means a sure-fire path to clarity, and no 392 trial is without its limitations. For example, the placebo-controlled dose-ranging RCT of 393 prenatal vitamin D in Bangladesh from Roth and colleagues was specifically designed to test 394 whether vitamin D improves infant growth in a setting where stunting is common (Roth et al., 395 2018b). It was not designed or powered to examine effects on uncommon maternal or 396 perinatal outcomes, and it is possible that the initiation of supplementation in the 2nd trimester

- 397 was too late to affect some outcomes such as preeclampsia (Roth et al., 2018b). Other aspects
- 398 of the trial may have limited its generalizability to the broader population of Bangladeshi
- 399 women (e.g., perhaps trial participants were healthier than average) or to populations outside
- 400 of Bangladesh (e.g., perhaps the trial participants' concurrent nutritional deficiencies
- 401 constrained the effects of vitamin D). **Place Figure 2 near here**
- 402 Unfortunately, systematic reviews and meta-analyses of RCTs can further confuse rather than 403 clarify the state of the evidence, as their conclusions can only be as robust as the underlying 404 evidence on which they are based (Roth et al., 2017). For example, authors of the recent 405 update of the Cochrane Collaboration systematic review of vitamin D in pregnancy had to 406 rely on mostly small trials of low or questionable quality to draw conclusions about the 407 effects of vitamin D (versus placebo) on metamol and peopletic evidence (Dalagias et al.
- 407 effects of vitamin D (versus placebo) on maternal and neonatal outcomes (Palacios et al.,
- 408 2019a). In summarizing one of the meta-analyses, Palacios *et al*. wrote that,
- 409 "supplementation with vitamin D probably reduces the risk of pre-eclampsia compared to no
- 410 intervention or placebo (risk ratio (RR 0.48, 95% CI 0.30 to 0.79)" and they considered this
- 411 to be based on "moderate-certainty evidence" (Palacios et al., 2019a). This conclusion is
- reiterated prominently in the abstract and plain-language summary, and if true, would be of
- 413 considerable public health importance. However, scrutiny of the four trials on which this
- 414 finding was based reveals the weakness of the conclusion. The aggregated sample size was
- 415 only 499 women (Palacios et al., 2019a), far lower than what would be required in a primary
- 416 prevention trial designed for precise estimation of effects of a prenatal intervention on 417 preeclampsia. Only one of the four trials reported having any type of prospective
- 418 ascertainment protocol and standardized case definition for preeclampsia (Behjat Sasan et al.,
- 419 2017), and all of the published trial reports lack sufficient information to confidently establish
- 420 the reliability of their findings (Asemi et al., 2013, Sablok et al., 2015, Behjat Sasan et al.,

- 421 2017, Naghshineh and Sheikhaliyan, 2016). Furthermore, reviews that incorporated other
- trials (including those in which control groups received a low-dose of vitamin D) do not
- 423 support a beneficial effect of additional vitamin D for prevention of preeclampsia, at least not
- 424 beyond the amount in conventional prenatal multiple micronutrient supplements (5-15
- 425 μ g/day) (Palacios et al., 2019b, Roth et al., 2017).

426 To date, there have not been *any* rigorous and adequately powered RCTs of prenatal vitamin 427 D supplementation for the prevention of hypertensive diseases of pregnancy or other adverse 428 maternal outcomes (Palacios et al., 2019b, Roth et al., 2017, Palacios et al., 2019a). Authors 429 of reviews or commentaries may conclude that vitamin D prevents pregnancy complications 430 if their meta-analysis was methodologically flawed (e.g., biased study selection, errors in data 431 abstraction) (Fogacci et al., 2019) or focused entirely on observational studies that cannot 432 provide evidence of causal effects (Tous et al., 2019, Zhou et al., 2017, Yuan et al., 2019). In 433 a recent article, Hollis recently wrote that, "Most of these clinical trials have validated the 434 positive effects of prenatal vitamin D on birth outcomes ...," (Hollis, 2019) citing four 435 published articles to support his claim: 1) an Iranian study that reported a lower frequency of preeclampsia, preterm delivery and adverse pregnancy outcomes at a hospital that conducted 436 437 screening for vitamin D deficiency and provided supplementation, compared to a control 438 hospital in another city (Rostami et al., 2018) (limitations of this study were highlighted in a 439 letter to the editor (Shub and McCarthy, 2019)); 2) a secondary analysis of VDAART that 440 examined asthma/wheeze outcomes but did not report on any birth outcomes (Wolsk et al., 441 2017b); 3) another secondary analysis of VDAART that found there was no effect of vitamin 442 D supplementation on preeclampsia risk based on the RCT design, but did find an association 443 between 25(OH)D and preeclampsia using a cohort analysis (Mirzakhani et al., 2016); and, 4) 444 an observational study of the association between 25(OH)D and preterm birth (McDonnell et 445 al., 2017). There are certainly many studies suggesting that prenatal vitamin D

- 446 supplementation *may* have benefits, including some small RCTs; however, an unbiased
- assessment must take stock of the entire body of evidence, taking into account study designand quality.

A pragmatic approach - setting the maternal vitamin D requirement to safeguard the fetal skeleton by targeting threshold 25-hydroxyvitamin D concentrations

451 MK proposed the possibility that given the various determinants of perinatal outcomes, 452 including personal, genetic and healthcare factors, as well as overall diet and nutrition, it may 453 be a too tall order to expect a single nutrient intervention to deliver dramatically improved 454 outcomes. This may be true both in low resource settings, where malnutrition is common, or 455 where there are no maternal or neonatal supplementation policies, but also in countries with 456 well-nourished, healthy mothers who have 25(OH)D status at baseline in excess of 50 nmol/L 457 and excellent obstetric care. Irrespective of the potential benefits of *additional* 25(OH)D to 458 enable the establishment and maintenance of a healthy pregnancy, the complete dependence 459 of the fetus and newborn infant on maternal 25(OH)D concentrations has been consistently reported (Hollis and Pittard, 1984b). It is widely accepted that at minimum, very low 460 461 25(OH)D (<25-30 nmol/L) during pregnancy should be prevented to protect fetal skeletal development (Munns et al., 2016). As cord 25(OH)D concentration is usually lower than the 462

463 corresponding maternal concentration (Hollis and Pittard, 1984b) and others, prevention of 464 maternal 25(OH)D below 25-30 nmol/L may not provide fetal and neonatal protection (Kiely 465 et al., 2016). Current recommendations for vitamin D during pregnancy do not consider the vitamin D requirement of newborn infants and assume the immediate availability of an 466 467 adequate supply from early life. Therefore, Kiely et al (2017a) proposed prevention of 468 neonatal vitamin D status <25-30 nmol/L, indicated by umbilical cord 25(OH)D, as a 469 potential target for defining maternal vitamin D requirements during pregnancy, consistent 470 with prevention of nutritional rickets (Munns et al., 2016). In a placebo-controlled dose-471 response RCT, O'Callaghan et al (2018) reported that maintaining maternal 25(OH)D 472 concentrations \geq 50 nmol/L at the end of pregnancy ensured that cord sera were all > 25 473 nmol/L. The vitamin D_3 intake required to maintain maternal 25(OH)D > 50 nmol/L in 474 almost all mothers was 30 µg/day (1200 IU) (O'Callaghan et al., 2018), which is twice the 475 current US and EU recommendation of 600 IU. This study confirmed suggestions from two 476 RCTs in Canada (March et al., 2015) and New Zealand (Grant et al., 2014), that although 10 477 µg vitamin D per day may prevent maternal 25(OH)D falling below 30 nmol/L, a minimum 478 of 25 µg/d might be needed to maintain newborn 25(OH)D at this concentration. Further 479 similar dose-response studies are required in different racial and ethnic groups and in various 480 settings to generate an inclusive estimate of maternal vitamin D requirements for the 481 prevention of neonatal deficiency. Adequate consideration of calcium intake is required in these studies. Calcium is infrequently considered in RCTs of vitamin D and perinatal health 482 483 although its role in the calcium metabolic system and maintenance of normal PTH 484 concentrations is linked to perinatal health (Hofmeyr et al., 2014, Hemmingway et al., 2018).

485 Conclusions

486 Laboratory science is driving our understanding of the role of vitamin D in healthy

487 pregnancy, most recently from the perspective of immune function. At a fundamental level,

the role of vitamin D in skeletal development has been accepted for many years, but the

489 particular needs of pregnant women and newborn infants, a high risk sector of the population,

- 490 have been underserved. While clinical practice guidelines are potentially more responsive to
- 491 new evidence, public health nutrition recommendations are infrequently updated, creating a
- lengthy gap between the clinical research evidence base and its translation into guidance.
- 493 National/international policy implementation is often slow or non-existent, contributing to a

494 wide dichotomy between the state of the art and public policy, manifested in gross

inequalities in health care provision and poor outcomes for at risk mothers and babies. This is

- 496 evidenced by the wide variation in vitamin D status and rates of nutritional rickets among at-
- 497 risk groups within and between countries.
- In the face of such uncertainty, where do we go from here? Even without strong evidence
- 499 from RCTs, it would be reasonable and safe for public health authorities to take a population
- 500 approach that aims to eliminate the prevalence of 25(OH)D <30 nmol/L and facilitate
- achievement of a personal target of 50 nmol/L, including among women of reproductive age
- 502 (Kiely et al., 2017a; Roth et al., 2018a). In this scenario, fortification of staple foods with
- 503 vitamin D (Roth et al., 2018a) and scale-up of use of antenatal multiple micronutrient

- supplements (Sudfeld and Smith, 2019) (which include modest amounts of vitamin D) will
- 505 likely achieve this aim and reduce the risk of severe vitamin D deficiency.
- 506 To determine if higher intakes of vitamin D are required in pregnancy, the optimal strategy

507 would be to conduct a large-scale RCT of prenatal vitamin D supplementation that goes

- beyond the scope of any previous or ongoing RCT: multi-country collaboration (including
- 509 both high- and lower-income settings), early first trimester (or preconception) enrolment,
- 510 factorial design with calcium, and designed and powered for uncommon maternal outcomes
- 511 (preeclampsia, intrauterine death), preterm birth, and longer-term child health outcomes
- 512 (including nutritional rickets). Such a trial would be financially costly and logistically
- challenging, but should be strongly considered by an international consortium of researchers
- 514 and funders.
- 515

- 516 References
- ABERCROMBIE, M., SHARY, J., EBELING, M., HOLLIS, B. & WAGNER, C. 2018.
 Analysis of the NICHD Vitamin D Pregnancy Cohort on a Per-Protocol vs.
- 519 Intent-to-Treat Basis: The Effect of Adherence on Trial Results. *Journal of Nutrition & Food* 520 *Sciences*, 8.
- ADAMS, J. S. & HEWISON, M. 2008. Unexpected actions of vitamin D: new perspectives
 on the regulation of innate and adaptive immunity. *Nat Clin Pract Endocrinol Metab*,
 4, 80-90.
- AL-GARAWI, A., CAREY, V. J., CHHABRA, D., MIRZAKHANI, H., MORROW, J.,
 LASKY-SU, J., QIU, W., LARANJO, N., LITONJUA, A. A. & WEISS, S. T. 2016.
 The Role of Vitamin D in the Transcriptional Program of Human Pregnancy. *PLoS One*, 11, e0163832.
- ARAVENA, T., CASTILLO, S., CARRASCO, X., MENA, I., LOPEZ, J., ROJAS, J. P.,
 ROSEMBERT, C., SCHROTER, C. & ABOITIZ, F. 2002. Williams syndrome:
 clinical, cytogenetical, neurophysiological and neuroanatomic study. *Rev. Med. Child*,
 130, 631-7.
- ARDAWI, M. S., NASRAT, H. A. & HS, B. A. A. 1997. Calcium-regulating hormones and
 parathyroid hormone-related peptide in normal human pregnancy and postpartum: a
 longitudinal study. *Eur J Endocrinol*, 137, 402-9.
- ASEMI, Z., SAMIMI, M., TABASSI, Z., SHAKERI, H. & ESMAILLZADEH, A. 2013.
 Vitamin D supplementation affects serum high-sensitivity C-reactive protein, insulin
 resistance, and biomarkers of oxidative stress in pregnant women. *J Nutr*, 143, 14328.
- BAKER, A. M., HAERI, S., CAMARGO, C. A., JR., ESPINOLA, J. A. & STUEBE, A. M.
 2010. A nested case-control study of midgestation vitamin D deficiency and risk of
 severe preeclampsia. *J Clin Endocrinol Metab*, 95, 5105-9.
- 542 BEHJAT SASAN, S., ZANDVAKILI, F., SOUFIZADEH, N. & BAYBORDI, E. 2017. The
 543 Effects of Vitamin D Supplement on Prevention of Recurrence of Preeclampsia in
 544 Pregnant Women with a History of Preeclampsia. *Obstet Gynecol Int*, 2017, 8249264.
- 545 BEST, C. M., PRESSMAN, E. K., QUEENAN, R. A., COOPER, E. & O'BRIEN, K. O.
 546 2019. Longitudinal changes in serum vitamin D binding protein and free 25547 hydroxyvitamin D in a multiracial cohort of pregnant adolescents. *J Steroid Biochem*548 *Mol Biol*, 186, 79-88.
- 549 BIKLE, D. D., GEE, E., HALLORAN, B. & HADDAD, J. G. 1984. Free 1,25550 dihydroxyvitamin D levels in serum from normal subjects, pregnant subjects, and
 551 subjects with liver disease. *J Clin Invest*, 74, 1966-71.
- BODNAR, L. M., SIMHAN, H. N., CATOV, J. M., ROBERTS, J. M., PLATT, R. W.,
 DIESEL, J. C. & KLEBANOFF, M. A. 2014. Maternal vitamin D status and the risk
 of mild and severe preeclampsia. *Epidemiology*, 25, 207-14.
- BRUSTAD, N., ELIASEN, A. U., STOKHOLM, J., BONNELYKKE, K., BISGAARD, H.
 & CHAWES, B. L. 2019. High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years. *JAMA*, 321, 1003-1005.
- 558 CARNEIRO, R. M., PREBEHALLA, L., TEDESCO, M. B., SEREIKA, S. M., HUGO, M.,
 559 HOLLIS, B. W., GUNDBERG, C. M., STEWART, A. F. & HORWITZ, M. J. 2010.
 560 Lactation and bone turnover: a conundrum of marked bone loss in the setting of
 561 coupled bone turnover. *J Clin Endocrinol Metab*, 95, 1767-1776.
- 562 CASHMAN, K. D., DOWLING, K. G., ŠKRABÁKOVÁ, Z., GONZALEZ-GROSS, M.,
- 563 VALTUEÑA, J., DE HENAUW, S., MORENO, L., DAMSGAARD, C. T.,
- 564 MICHAELSEN, K. F., MØLGAARD, C., JORDE, R., GRIMNES, G.,

565	MOSCHONIS, G., MAVROGIANNI, C., MANIOS, Y., THAMM, M., MENSINK,
566	G. B., RABENBERG, M., BUSCH, M. A., COX, L., MEADOWS, S., GOLDBERG,
567	G., PRENTICE, A., DEKKER, J. M., NIJPELS, G., PILZ, S., SWART, K. M., VAN
568	SCHOOR, N. M., LIPS, P., EIRIKSDOTTIR, G., GUDNASON, V., COTCH, M. F.,
569	KOSKINEN, S., LAMBERG-ALLARDT, C., DURAZO-ARVIZU, R. A., SEMPOS,
570	C. T. & KIELY, M. 2016. Vitamin D deficiency in Europe: pandemic? Am J Clin
571	Nutr, 103, 1033-44.
572	CASHMAN, K. D., SHEEHY, T. & O'NEILL, C. M. 2019. Is vitamin D deficiency a public
573	health concern for low middle income countries? A systematic literature review. Eur J
574	Nutr, 58, 433-453.
575	CHAN, S. Y., SUSARLA, R., CANOVAS, D., VASILOPOULOU, E., OHIZUA, O.,
576	MCCABE, C. J., HEWISON, M. & KILBY, M. D. 2015. Vitamin D promotes human
577	extravillous trophoblast invasion in vitro. <i>Placenta</i> , 36, 403-409.
578	CHAWES, B. L., BØNNELYKKE, K., STOKHOLM, J. & ET AL. 2016. Effect of vitamin
579	D3 supplementation during pregnancy on risk of persistent wheeze in the offspring: A
580	randomized clinical trial. JAMA, 315, 353-361.
581	CHI, A., WILDFIRE, J., MCLOUGHLIN, R., WOOD, R. A., BLOOMBERG, G. R.,
582	KATTAN, M., GERGEN, P., GOLD, D. R., WITTER, F., CHEN, T., HOLICK, M.,
583	VISNESS, C., GERN, J. & O'CONNOR, G. T. 2011. Umbilical cord plasma 25-
584	hydroxyvitamin D concentration and immune function at birth: the Urban
585	Environment and Childhood Asthma study. Clin Exp Allergy, 41, 842-50.
586	CHUN, R. F., LIU, P. T., MODLIN, R. L., ADAMS, J. S. & HEWISON, M. 2014a. Impact
587	of vitamin D on immune function: lessons learned from genome-wide analysis. Front
588	<i>Physiol</i> , 5, 151.
589	CHUN, R. F., LIU, P. T., MODLIN, R. L., ADAMS, J. S. & HEWISON, M. 2014b. Impact
590	of vitamin D on immune function: lessons learned from genome-wide analysis. Front
591	<i>Physiol</i> , 5, 151-151.
592	COOPER, C., HARVEY, N. C., BISHOP, N. J., KENNEDY, S., PAPAGEORGHIOU, A. T.,
593	SCHOENMAKERS, I., FRASER, R., GANDHI, S. V., CARR, A., D'ANGELO, S.,
594	CROZIER, S. R., MOON, R. J., ARDEN, N. K., DENNISON, E. M., GODFREY, K.
595	M., INSKIP, H. M., PRENTICE, A., MUGHAL, M. Z., EASTELL, R., REID, D. M.,
596	JAVAID, M. K. & GROUP, M. S. 2016. Maternal gestational vitamin D
597	supplementation and offspring bone health (MAVIDOS): a multicentre, double-blind,
598	randomised placebo-controlled trial. <i>Lancet Diabetes Endocrinol</i> , 4, 393-402.
599	CREO, A. L., THACHER, T. D., PETTIFOR, J. M., STRAND, M. A. & FISCHER, P. R.
600	2017. Nutritional rickets around the world: an update. <i>Paediatr Int Child Health</i> , 37,
601	84-98.
602	DAWODU, A., SAADI, H. F., BEKDACHE, G., JAVED, Y., ALTAYE, M. & HOLLIS, B.
603	W. 2013. Randomized controlled trial (RCT) of vitamin D supplementation in
604	pregnancy in a population with endemic vitamin D deficiency. <i>J Clin Endocrinol</i>
605	Metab, 98, 2337-46.
606	FLEISCHMAN, A. R., ROSEN, J. F., COLE, J., SMITH, C. M. & DELUCA, H. F. 1980.
607 608	Maternal and Fetal Serum 1,25- dihydroxy vitamin D levels at term. <i>J of Pediatr</i> , 97, 640-2.
608 609	
610	FOGACCI, S., FOGACCI, F., BANACH, M., MICHOS, E. D., HERNANDEZ, A. V., LIP, G. Y. H., BLAHA, M. J., TOTH, P. P., BORGHI, C., CICERO, A. F. G., LIPID &
611	BLOOD PRESSURE META-ANALYSIS COLLABORATION, G. 2019. Vitamin D
612	supplementation and incident preeclampsia: A systematic review and meta-analysis of
613	randomized clinical trials. <i>Clin Nutr</i> .
015	

- GANGULY, A., TAMBLYN, J. A., FINN-SELL, S., CHAN, S. Y., WESTWOOD, M.,
 GUPTA, J., KILBY, M. D., GROSS, S. R. & HEWISON, M. 2018. Vitamin D, the
 placenta and early pregnancy: effects on trophoblast function. *J Endocrinol*, 236,
 R93-r103.
- 618 GRANT, C. C., STEWART, A. W., SCRAGG, R., MILNE, T., ROWDEN, J., EKEROMA,
 619 A., WALL, C., MITCHELL, E. A., CRENGLE, S., TRENHOLME, A., CRANE, J. &
 620 CAMARGO, C. A., JR. 2014. Vitamin D during pregnancy and infancy and infant
 621 serum 25-hydroxyvitamin D concentration. *Pediatrics*, 133, e143-53.
- 622 GRAY, T. K., LESTER, G. E. & LORENC, R. S. 1979. Evidence for extra-renal 1 alpha-623 hydroxylation of 25-hydroxyvitamin D3 in pregnancy. *Science*, 204, 1311-3.
- 624 GREY, A. & BOLLAND, M. J. 2016. Inaccurate dissemination of the MAVIDOS trial
 625 results. *Lancet Diabetes Endocrinol*, 4, 481.
- 626 GUVEN, A., ECEVIT, A., SOZER, O., TARCAN, A., TARCAN, A. & OZBEK, N. 2012.
 627 Correlation between the cord vitamin D levels and regulatory T cells in newborn
 628 infants. *Eur J Pediatr*, 171, 1161-6.
- HADDOW, J. E., NEVEUX, L. M., PALOMAKI, G. E., LAMBERT-MESSERLIAN, G.,
 CANICK, J. A., GRENACHE, D. G. & LU, J. 2011. The Relationship between PTH
 and 25-Hydroxy Vitamin D Early in Pregnancy. *Clin Endocrinol (Oxf)*.
- HAWRYLOWICZ, C. M. & SANTOS, A. F. 2019. Vitamin D: can the sun stop the atopic
 epidemic? *Curr Opin Allergy Clin Immunol*.
- HEANEY, R. P. 2014. Guidelines for optimizing design and analysis of clinical studies of
 nutrient effects. *Nutr Rev*, 72, 48-54.
- HEMMINGWAY, A., KENNY, L. C., MALVISI, L. & KIELY, M. E. 2018. Exploring the
 concept of functional vitamin D deficiency in pregnancy: impact of the interaction
 between 25-hydroxyvitamin D and parathyroid hormone on perinatal outcomes. *Am J Clin Nutr*, 108, 821-9.
- HEWISON, M. 2018. The earlier the better: preconception vitamin D and protection against
 pregnancy loss. *Lancet Diabetes Endocrinol*, 6, 680-681.
- HILLMAN, L. S., SALMONS, S. & DOKOH, S. 1985. Serum 1,25-dihydroxyvitamin D
 concentrations in premature infants: preliminary results. *Calcif Tissue Int*, 37, 223-7.
- HOFMEYR, G. J., BELIZÁN, J. M., VON DADELSZEN, P. & CALCIUM AND PRE ECLAMPSIA (CAP) STUDY GROUP 2014. Low-dose calcium supplementation for
 preventing pre-eclampsia: a systematic review and commentary. *BJOG*, 121, 951-7.
- HOLLIS, B. W. 2019. Vitamin D status during pregnancy: The importance of getting it right.
 EBioMedicine, 39, 23-24.
- HOLLIS, B. W., JOHNSON, D., HULSEY, T. C., EBELING, M. & WAGNER, C. L. 2011.
 Vitamin D supplementation during pregnancy: Double blind, randomized clinical trial
 of safety and effectiveness. *J Bone Miner Res*, 26, 2341-57.
- HOLLIS, B. W. & PITTARD, W. B. 1984a. Evaluation of the total fetomaternal vitamin D
 relationships at term: Evidence for racial differences. *J Clin Endorcrinol Metab*, 59,
 654 652-657.
- HOLLIS, B. W. & PITTARD, W. B., 3RD 1984b. Evaluation of the total fetomaternal
 vitamin D relationships at term: evidence for racial differences. *J Clin Endocrinol Metab*, 59, 652-7.
- HOLLIS, B. W. & WAGNER, C. L. 2013. Vitamin D and Pregnancy: Skeletal Effects,
 Nonskeletal Effects, and Birth Outcomes. *Calcified tissue international*, 92, 128-39.
- HOLLIS, B. W. & WAGNER, C. L. 2017a. New insights into the vitamin D requirements
 during pregnancy. *Bone Res*, 5, 17030.

- HOLLIS, B. W. & WAGNER, C. L. 2017b. Vitamin D supplementation during pregnancy:
 Improvements in birth outcomes and complications through direct genomic alteration.
 Mol Cell Endocrinol, 453, 113-130.
- HORNSBY, E., PFEFFER, P. E., LARANJO, N., CRUIKSHANK, W., TUZOVA, M.,
 LITONJUA, A. A., WEISS, S. T., CAREY, V. J., O'CONNOR, G. &
- LITONJUA, A. A., WEISS, S. T., CAREY, V. J., O'CONNOR, G. &
 HAWRYLOWICZ, C. 2018. Vitamin D supplementation during pregnancy: Effect on
 the neonatal immune system in a randomized controlled trial. *J Allergy Clin Immunol*,
 141, 269-278 e1.
- 670 INSTITUTE OF MEDICINE 2011. Dietary reference intakes for Calcium and Vitamin D.
 671 Washington (DC): National Academies Press.
- JEFFERY, L. E., BURKE, F., MURA, M., ZHENG, Y., QURESHI, O. S., HEWISON, M.,
 WALKER, L. S. K., LAMMAS, D. A., RAZA, K. & SANSOM, D. M. 2009. 1,25Dihydroxyvitamin D3 and IL-2 Combine to Inhibit T Cell Production of
- Inflammatory Cytokines and Promote Development of Regulatory T Cells Expressing
 CTLA-4 and FoxP3. *The Journal of Immunology*, 183, 5458-5467.
- JI, J., ZHAI, H., ZHOU, H., SONG, S., MOR, G. & LIAO, A. 2019. The role and mechanism
 of vitamin D-mediated regulation of Treg/Th17 balance in recurrent pregnancy loss.
 Am J Reprod Immunol, 81, e13112.
- KALUDJEROVIC, J. & VIETH, R. 2010. Relationship between vitamin D during perinatal
 development and health. *J Midwifery Womens Health*, 55, 550-60.
- KELLY, R. S., CHAWES, B. L., GUO, F., ZHANG, L., BLIGHE, K., LITONJUA, A. A.,
 RABY, B. A., LEVY, B. D., RAGO, D., STOKHOLM, J., BONNELYKKE, K.,
 BISGAARD, H., ZHOU, X., LASKY-SU, J. A. & WEISS, S. T. 2019. The role of the
 17q21 genotype in the prevention of early childhood asthma and recurrent wheeze by
 vitamin D. *Eur Respir J*, 54.
- KIELY, M., HEMMINGWAY, A. & O'CALLAGHAN, K. M. 2017a. Vitamin D in
 pregnancy: current perspectives and future directions. *Ther Adv Musculoskelet Dis*, 9,
 145-54.
- KIELY, M., O'DONOVAN, S. M., KENNY, L. C., HOURIHANE, J. O., IRVINE, A. D. &
 MURRAY, D. M. 2017b. Vitamin D metabolite concentrations in umbilical cord
 blood serum and associations with clinical characteristics in a large prospective
 mother-infant cohort in Ireland. *J Steroid Biochem Mol Biol*, 167, 162-8.
- KIELY, M. E., ZHANG, J. Y., KINSELLA, M., KHASHAN, A. S. & KENNY, L. C. 2016.
 Vitamin D status is associated with uteroplacental dysfunction indicated by preeclampsia and small-for-gestational-age birth in a large prospective pregnancy cohort
 in Ireland with low vitamin D status. *Am J Clin Nutr*, 104, 354-61.
- KNABL, J., VATTAI, A., YE, Y., JUECKSTOCK, J., HUTTER, S., KAINER, F.,
 MAHNER, S. & JESCHKE, U. 2017. Role of Placental VDR Expression and
 Function in Common Late Pregnancy Disorders. *Int J Mol Sci*, 18.
- KOVACS, C. S. 2014. Bone development and mineral homeostasis in the fetus and neonate:
 roles of the calciotropic and phosphotropic hormones. *Physiol Rev*, 94, 1143-218.
- KWAK-KIM, J., SKARIAH, A., WU, L., SALAZAR, D., SUNG, N. & OTA, K. 2016.
 Humoral and cellular autoimmunity in women with recurrent pregnancy losses and
 repeated implantation failures: A possible role of vitamin D. *Autoimmun Rev*, 15, 943706
- 107 LIPS, P., CASHMAN, K. D., LAMBERG-ALLARDT, C., BISCHOFF-FERRARI, H. A.,
 108 OBERMAYER-PIETSCH, B. R., BIANCHI, M., STEPAN, J., EL-HAJJ
 109 FULEIHAN, G. & BOUILLON, R. 2019. MANAGEMENT OF ENDOCRINE
- 710 DISEASE: Current vitamin D status in European and Middle East countries and

- strategies to prevent vitamin D deficiency; a position statement of the European
 Calcified Tissue Society. *Eur J Endocrinol.*
- LITONJUA, A. A., CAREY, V. J., LARANJO, N., HARSHFIELD, B. J., MCELRATH, T.
 F., O'CONNOR, G. T., SANDEL, M., IVERSON, R. E., JR., LEE-PARITZ, A.,
- 715 STRUNK, R. C., BACHARIER, L. B., MACONES, G. A., ZEIGER, R. S.,
- SCHATZ, M., HOLLIS, B. W., HORNSBY, E., HAWRYLOWICZ, C., WU, A. C. &
 WEISS, S. T. 2016. Effect of Prenatal Supplementation With Vitamin D on Asthma
 or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized
 Clinical Trial. *JAMA*, 315, 362-70.
- LITONJUA, A. A., CAREY, V. J., LARANJO, N., STUBBS, B. J., MIRZAKHANI, H.,
 O'CONNOR, G. T., SANDEL, M., BEIGELMAN, A., BACHARIER, L. B.,
 ZEIGER, R. S., SCHATZ, M., HOLLIS, B. W. & WEISS, S. T. 2020. Six-Year
 Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction. *N Engl J Med*,
 382, 525-533.
- LIU, N. Q. & HEWISON, M. 2012. Vitamin D, the placenta and pregnancy. *Arch Biochem Biophys*, 523, 37-47.
- LIU, N. Q., KAPLAN, A. T., LAGISHETTY, V., OUYANG, Y. B., OUYANG, Y.,
 SIMMONS, C. F., EQUILS, O. & HEWISON, M. 2011. Vitamin D and the
 regulation of placental inflammation. *Journal of immunology*, 186, 5968-74.
- LIU, N. Q., OUYANG, Y., BULUT, Y., LAGISHETTY, V., CHAN, S. Y., HOLLIS, B. W.,
 WAGNER, C., EQUILS, O. & HEWISON, M. 2013. Dietary vitamin D restriction in
 pregnant female mice is associated with maternal hypertension and altered placental
 and fetal development. *Endocrinology*, 154, 2270-80.
- LIU, P. T., STENGER, S., LI, H., WENZEL, L., TAN, B. H., KRUTZIK, S. R., OCHOA, M.
 T., SCHAUBER, J., WU, K., MEINKEN, C., KAMEN, D. L., WAGNER, M., BALS,
 R., STEINMEYER, A., ZUGEL, U., GALLO, R. L., EISENBERG, D., HEWISON,
 M., HOLLIS, B. W., ADAMS, J. S., BLOOM, B. R. & MODLIN, R. L. 2006. Tolllike receptor triggering of a vitamin D-mediated human antimicrobial response. *Science*, 311, 1770-3.
- 740 MACDONALD, C., UPTON, T., HUNT, P., PHILLIPS, I., KAUFMANN, M.,
- FLORKOWSKI, C., SOULE, S. & JONES, G. 2020. Vitamin D supplementation in
 pregnancy: A word of caution. Familial hypercalcaemia due to disordered vitamin D
 metabolism. *Ann Clin Biochem*, 4563219897691.
- MARCH, K. M., CHEN, N. N., KARAKOCHUK, C. D., SHAND, A. W., INNIS, S. M.,
 VON DADELSZEN, P., BARR, S. I., LYON, M. R., WHITING, S. J., WEILER, H.
 A. & GREEN, T. J. 2015. Maternal vitamin D₃ supplementation at 50 ug/d protects
 against low serum 25-hydroxyvitamin D in infants at 8 wk of age: a randomized
 controlled trial of 3 doses of vitamin D beginning in gestation and continued in
 lactation. *Am J Clin Nutr*, 102, 402-10.
- MCDONNELL, S. L., BAGGERLY, K. A., BAGGERLY, C. A., ALIANO, J. L., FRENCH,
 C. B., BAGGERLY, L. L., EBELING, M. D., RITTENBERG, C. S., GOODIER, C.
 G., MATEUS NINO, J. F., WINELAND, R. J., NEWMAN, R. B., HOLLIS, B. W. &
 WAGNER, C. L. 2017. Maternal 25(OH)D concentrations >/=40 ng/mL associated
 with 60% lower preterm birth risk among general obstetrical patients at an urban
 medical center. *PLoS One*, 12, e0180483.
- MIRZAKHANI, H., LITONJUA, A. A., MCELRATH, T. F., O'CONNOR, G., LEEPARRITZ, A., IVERSON, R., MACONES, G., STRUNK, R. C., BACHARIER, L.
 B., ZEIGER, R., HOLLIS, B. W., HANDY, D. E., SHARMA, A., LARANJO, N.,
 CAREY, V., QIU, W., SANTOLINI, M., LIU, S., CHHABRA, D.,
- 759 CARET, V., QIU, W., SANTOLINI, M., LIU, S., CHHABRA, D.,
 760 ENQUOBAHRIE, D. A., WILLIAMS, M. A., LOSCALZO, J. & WEISS, S. T. 2016.

- Early pregnancy vitamin D status and risk of preeclampsia. *J Clin Invest*, 126, 47024715.
- MOR, G. & CARDENAS, I. 2010. The immune system in pregnancy: a unique complexity.
 Am J Reprod Immunol, 63, 425-33.
- MUNNS, C. F., SHAW, N., KIELY, M., SPECKER, B. L., THACHER, T. D., OZONO, K., 765 MICHIGAMI, T., TIOSANO, D., MUGHAL, M. Z., MÄKITIE, O., RAMOS-766 767 ABAD, L., WARD, L., DIMEGLIO, L. A., ATAPATTU, N., CASSINELLI, H., 768 BRAEGGER, C., PETTIFOR, J. M., SETH, A., IDRIS, H. W., BHATIA, V., FU, J., 769 GOLDBERG, G., SÄVENDAHL, L., KHADGAWAT, R., PLUDOWSKI, P., 770 MADDOCK, J., HYPPÖNEN, E., ODUWOLE, A., FREW, E., AGUIAR, M., 771 TULCHINSKY, T., BUTLER, G. & HÖGLER, W. 2016. Global consensus 772 recommendations on prevention and management of nutritional rickets. J Clin 773 Endocrinol Metab, 101, 394-415.
- NAGHSHINEH, E. & SHEIKHALIYAN, S. 2016. Effect of vitamin D supplementation in
 the reduce risk of preeclampsia in nulliparous women. *Adv Biomed Res*, 5, 7.
- NIKOLIC, T. & ROEP, B. O. 2013. Regulatory multitasking of tolerogenic dendritic cells lessons taken from vitamin d3-treated tolerogenic dendritic cells. *Front Immunol*, 4, 113.
- NOVAKOVIC, B., SIBSON, M., NG, H. K., MANUELPILLAI, U., RAKYAN, V., DOWN,
 T., BECK, S., FOURNIER, T., EVAIN-BRION, D., DIMITRIADIS, E., CRAIG, J.
 M., MORLEY, R. & SAFFERY, R. 2009. Placenta-specific methylation of the
 vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active
 vitamin D levels at the fetomaternal interface. *J Biol Chem*, 284, 14838-48.
- O'CALLAGHAN, K. M., HENNESSY, Á., HULL, G. L. J., HEALY, K., RITZ, C., KENNY,
 L. C., CASHMAN, K. D. & KIELY, M. E. 2018. Estimation of the maternal vitamin
 D intake that maintains circulating 25-hydroxyvitamin D in late gestation at a
 concentration sufficient to keep umbilical cord sera ≥25-30 nmol/L: a dose-response,
 double-blind, randomized placebo-controlled trial in pregnant women at northern
 latitude. Am J Clin Nutr, 108, 77-91.
- OLMOS-ORTIZ, A., AVILA, E., DURAND-CARBAJAL, M. & DIAZ, L. 2015. Regulation
 of calcitriol biosynthesis and activity: focus on gestational vitamin D deficiency and
 adverse pregnancy outcomes. *Nutrients*, 7, 443-80.
- PALACIOS, C., KOSTIUK, L. K. & PENA-ROSAS, J. P. 2019a. Vitamin D
 supplementation for women during pregnancy. *Cochrane Database Syst Rev*, 7, CD008873.
- PALACIOS, C., TRAK-FELLERMEIER, M. A., MARTINEZ, R. X., LOPEZ-PEREZ, L.,
 LIPS, P., SALISI, J. A., JOHN, J. C. & PENA-ROSAS, J. P. 2019b. Regimens of
 vitamin D supplementation for women during pregnancy. *Cochrane Database Syst Rev*, 10, CD013446.
- PAPAPETROU, P. D. 2010. The interrelationship of serum 1,25-dihydroxyvitamin D, 25 hydroxyvitamin D and 24,25-dihydroxyvitamin D in pregnancy at term: a meta analysis. *Hormones (Athens)*, 9, 136-44.
- PENNA, G., AMUCHASTEGUI, S., GIARRATANA, N., DANIEL, K. C., VULCANO, M.,
 SOZZANI, S. & ADORINI, L. 2007. 1,25-Dihydroxyvitamin D3 Selectively
 Modulates Tolerogenic Properties in Myeloid but Not Plasmacytoid Dendritic Cells.
 The Journal of Immunology, 178, 145-153.
- PENNA, G., RONCARI, A., AMUCHASTEGUI, S., DANIEL, K. C., BERTI, E.,
 COLONNA, M. & ADORINI, L. 2005. Expression of the inhibitory receptor ILT3 on
 dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by
 1,25-dihydroxyvitamin D3. *Blood*, 106, 3490-7.

- PFEFFER, P. E. & HAWRYLOWICZ, C. M. 2018. Vitamin D in Asthma: Mechanisms of
 Action and Considerations for Clinical Trials. *Chest*, 153, 1229-1239.
- POWE, C. E., SEELY, E. W., RANA, S., BHAN, I., ECKER, J., KARUMANCHI, S. A. &
 THADHANI, R. 2010. First Trimester Vitamin D, Vitamin D Binding Protein, and
 Subsequent Preeclampsia. *Hypertension*, HYPERTENSIONAHA.110.158238.
- PRENTICE, A. 2013. Nutritional rickets around the world. *J Steroid Biochem Mol Biol*, 136,
 201-6.
- RACICOT, K., KWON, J. Y., ALDO, P., SILASI, M. & MOR, G. 2014. Understanding the
 complexity of the immune system during pregnancy. *Am J Reprod Immunol*, 72, 107 16.
- RITCHIE, L. D., FUNG, E. B., HALLORAN, B. P., TURNLUND, J. R., VAN LOAN, M.
 D., CANN, C. E. & KING, J. C. 1998. A longitudinal study of calcium homeostasis
 during human pregnancy and lactation and after resumption of menses. *Am J Clin Nutr*, 67, 693-701.
- ROBINSON, C. J., ALANIS, M. C., WAGNER, C. L., HOLLIS, B. W. & JOHNSON, D. D.
 2010. Plasma 25-hydroxyvitamin D levels in early-onset severe preeclampsia. *Am J Obstet Gynecol*, 203, 366 e1-6.
- ROSTAMI, M., RAMEZANI TEHRANI, F., SIMBAR, M., BIDHENDI YARANDI, R.,
 MINOOEE, S., HOLLIS, B. W. & HOSSEINPANAH, F. 2018. Effectiveness of
 prenatal vitamin D deficiency screening and treatment program: a stratified
 randomized field trial. *J Clin Endocrinol Metab*.
- ROTH, D. E., ABRAMS, S. A., ALOIA, J., BERGERON, G., BOURASSA, M. W.,
 BROWN, K. H., CALVO, M. S., CASHMAN, K. D., COMBS, G., DE-REGIL, L.
 M., JEFFERDS, M. E., JONES, K. S., KAPNER, H., MARTINEAU, A. R.,
 NEUFELD, L. M., SCHLEICHER, R. L., THACHER, T. D. & WHITING, S. J.
 2018a. Global prevalence and disease burden of vitamin D deficiency: a roadmap for
 action in low- and middle-income countries. *Ann N Y Acad Sci*, 1430, 44-79.
- ROTH, D. E., LEUNG, M., MESFIN, E., QAMAR, H., WATTERWORTH, J. & PAPP, E.
 2017. Vitamin D supplementation during pregnancy: state of the evidence from a systematic review of randomised trials. *BMJ*, 359, j5237.
- ROTH, D. E., MORRIS, S. K., ZLOTKIN, S., GERNAND, A. D., AHMED, T., SHANTA,
 S. S., PAPP, E., KORSIAK, J., SHI, J., ISLAM, M. M., JAHAN, I., KEYA, F. K.,
 WILLAN, A. R., WEKSBERG, R., MOHSIN, M., RAHMAN, Q. S., SHAH, P. S.,
 MURPHY, K. E., STIMEC, J., PELL, L. G., QAMAR, H. & AL MAHMUD, A.
 2018b. Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth. N *Engl J Med*, 379, 535-546.
- SABLOK, A., BATRA, A., THARIANI, K., BATRA, A., BHARTI, R., AGGARWAL, A.
 R., KABI, B. C. & CHELLANI, H. 2015. Supplementation of vitamin D in pregnancy and its correlation with feto-maternal outcome. *Clin Endocrinol (Oxf)*, 83, 536-41.
- SARAFIN, K., DURAZO-ARVIZU, R., TIAN, L., PHINNEY, K. W., TAI, S., CAMARA, J.
 E., MERKEL, J., GREEN, E., SEMPOS, C. T. & BROOKS, S. P. 2015.
 Standardizing 25-hydroxyvitamin D values from the Canadian Health Measures
- 853 Survey. Am J Clin Nutr, 102, 1044-50.
- SCHLEICHER, R. L., STERNBERG, M. R., LOOKER, A. C., YETLEY, E. A., LACHER,
 D. A., SEMPOS, C. T., TAYLOR, C. L., DURAZO-ARVIZU, R. A., MAW, K. L.,
 CHAUDHARY-WEBB, M., JOHNSON, C. L. & PFEIFFER, C. M. 2016. National
 estimates of serum total 25-hydroxyvitamin D and metabolite concentrations
 measured by liquid chromatography-tandem mass spectrometry in the US population
 during 2007-2010. J Nutr, 146, 1051-61.

- SCHULZ, E. V., CRUZE, L., WEI, W., GEHRIS, J. & WAGNER, C. L. 2017. Maternal
 vitamin D sufficiency and reduced placental gene expression in angiogenic
 biomarkers related to comorbidities of pregnancy. *J Steroid Biochem Mol Biol.*
- SEKI, K., FURUYA, K., MAKIMURA, N., MITSUI, C., HIRATA, J. & NAGATA, I. 1994.
 Cord blood levels of calcium-regulating hormones and osteocalcin in premature
 infants. *J Perinat Med*, 22, 189-94.
- SHARIF, K., SHARIF, Y., WATAD, A., YAVNE, Y., LICHTBROUN, B., BRAGAZZI, N.
 L., AMITAL, H. & SHOENFELD, Y. 2018. Vitamin D, autoimmunity and recurrent pregnancy loss: More than an association. *Am J Reprod Immunol*, 80, e12991.
- SHUB, A. & MCCARTHY, E. A. 2019. Letter to the Editor: "Effectiveness of Prenatal
 Vitamin D Deficiency Screening and Treatment Program: A Stratified Randomized
 Field Trial". *J Clin Endocrinol Metab*, 104, 337-338.
- STUKES, T. M., SHARY, J. R., WEI, W., EBELING, M. D., DEZSI, K. B., SHARY, F. S.,
 FORESTIERI, N. E., HOLLIS, B. W. & WAGNER, C. L. 2016. Circulating
 Cathelicidin Concentrations in a Cohort of Healthy Children: Influence of Age, Body
 Composition, Gender and Vitamin D Status. *PLoS One*, 11, e0152711.
- SUDFELD, C. R. & SMITH, E. R. 2019. New Evidence Should Inform WHO Guidelines on
 Multiple Micronutrient Supplementation in Pregnancy. *J Nutr*, 149, 359-361.
- TAMBLYN, J. A., HEWISON, M., WAGNER, C. L., BULMER, J. N. & KILBY, M. D.
 2015. Immunological role of vitamin D at the maternal-fetal interface. *J Endocrinol*, 224, R107-21.
- TAMBLYN, J. A., JENKINSON, C., LARNER, D. P., HEWISON, M. & KILBY, M. D.
 2018. Serum and urine vitamin D metabolite analysis in early preeclampsia. *Endocr Connect*, 7, 199-210.
- THACHER, T. D., FISCHER, P. R., STRAND, M. A. & PETTIFOR, J. M. 2006. Nutritional
 rickets around the world: causes and future directions. *Ann Trop Paediatr*, 26, 1-16.
- TOUS, M., VILLALOBOS, M., IGLESIAS, L., FERNANDEZ-BARRES, S. & ARIJA, V.
 2019. Vitamin D status during pregnancy and offspring outcomes: a systematic
 review and meta-analysis of observational studies. *Eur J Clin Nutr*.
- TSUPRYKOV, O., BUSE, C., SKOBLO, R. & HOCHER, B. 2019. Comparison of free and total 25-hydroxyvitamin D in normal human pregnancy. *The Journal of Steroid Biochemistry and Molecular Biology*, 190, 29-36.
- URRY, Z., CHAMBERS, E. S., XYSTRAKIS, E., DIMELOE, S., RICHARDS, D. F.,
 GABRYŠOVÁ, L., CHRISTENSEN, J., GUPTA, A., SAGLANI, S., BUSH, A.,
 O'GARRA, A., BROWN, Z. & HAWRYLOWICZ, C. M. 2012. The role of 1α,25dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3+and IL10+CD4+T cells. *European Journal of Immunology*, 42, 2697-2708.
- VAN DER AAR, A. M. G., SIBIRYAK, D. S., BAKDASH, G., VAN CAPEL, T. M. M.,
 VAN DER KLEIJ, H. P. M., OPSTELTEN, D.-J. E., TEUNISSEN, M. B. M.,
 KAPSENBERG, M. L. & DE JONG, E. C. 2011. Vitamin D3 targets epidermal and
- dermal dendritic cells for induction of distinct regulatory T cells. 127, 1532-1540.e7.
 VASILIOU, J. E., LUI, S., WALKER, S. A., CHOHAN, V., XYSTRAKIS, E., BUSH, A.,
- VASILIOU, J. E., LUI, S., WALKER, S. A., CHOHAN, V., ATSTRAKIS, E., BUSH, A.,
 HAWRYLOWICZ, C. M., SAGLANI, S. & LLOYD, C. M. 2014. Vitamin D
 deficiency induces Th2 skewing and eosinophilia in neonatal allergic airways disease.
 Allergy, 69, 1380-9.
- 905 VIJAYENDRA CHARY, A., HEMALATHA, R., SESHACHARYULU, M., VASUDEVA
 906 MURALI, M., JAYAPRAKASH, D. & DINESH KUMAR, B. 2015a. Reprint of
 907 "Vitamin D deficiency in pregnant women impairs regulatory T cell function". J
 908 Steroid Biochem Mol Biol, 148, 194-201.

- 909 VIJAYENDRA CHARY, A., HEMALATHA, R., SESHACHARYULU, M., VASUDEVA
 910 MURALI, M., JAYAPRAKASH, D. & DINESH KUMAR, B. 2015b. Vitamin D
 911 deficiency in pregnant women impairs regulatory T cell function. *J Steroid Biochem*912 *Mol Biol*, 147, 48-55.
- WAGNER, C. L. & HOLLIS, B. W. 2011. Beyond PTH: assessing vitamin D status during
 early pregnancy. *Clinical Endocrinology*, 75, 285-6.
- WAGNER, C. L., MCNEIL, R., HAMILTON, S. A., WINKLER, J., RODRIGUEZ COOK,
 C., WARNER, G., BIVENS, B., DAVIS, D. J., SMITH, P. G., MURPHY, M.,
 SHARY, J. R. & HOLLIS, B. W. 2013a. A randomized trial of vitamin D
 supplementation in 2 community health center networks in South Carolina. *Am J Obstet Gynecol*, 208, 137 e1-137 e13.
- WAGNER, C. L., MCNEIL, R. B., JOHNSON, D. D., HULSEY, T. C., EBELING, M.,
 ROBINSON, C., HAMILTON, S. A. & HOLLIS, B. W. 2013b. Health characteristics
 and outcomes of two randomized vitamin D supplementation trials during pregnancy:
 a combined analysis. *J Steroid Biochem Mol Biol*, 136, 313-20.
- WEISS, S., WOLSK, H., MIRZAKHANI, H., HOLLIS, B., CAREY, V., LITONJUA, A. &
 GROUP., F. T. V. T. Asthma/Wheeze and preeclampsia outcomes in the VDAART
 Trial: The influcence of baseline and treatment levels of vitamin D on treatment
 response. The Vitamin D Workshop, March 29-31, 2016 2016 Boston, MA.
 www.vitamindworkshop.org.
- WEISS, S. T. & LITONJUA, A. A. 2017. Vitamin D in Host Defense: Implications for
 Future Research. *Am J Respir Cell Mol Biol*, 56, 692-693.
- WHITEHEAD, M., LANE, G., YOUNG, O., CAMPBELL, S., ABEYASEKERA, G.,
 HILLYARD, C. J., MACINTYRE, I., PHANG, K. G. & STEVENSON, J. C. 1981.
 Interrelations of calcium-regulating hormones during normal pregnancy. *Br Med J*(*Clin Res Ed*), 283, 10-2.
- WOLSK, H. M., CHAWES, B. L., LITONJUA, A. A., HOLLIS, B. W., WAAGE, J.,
 STOKHOLM, J., BONNELYKKE, K., BISGAARD, H. & WEISS, S. T. 2017a.
 Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early
 childhood: A combined analysis of two randomized controlled trials. *PLoS One*, 12,
 e0186657.
- WOLSK, H. M., HARSHFIELD, B. J., LARANJO, N., CAREY, V. J., O'CONNOR, G.,
 SANDEL, M., STRUNK, R. C., BACHARIER, L. B., ZEIGER, R. S., SCHATZ, M.,
 HOLLIS, B. W., WEISS, S. T. & LITONJUA, A. A. 2017b. Vitamin D
 supplementation in pregnancy, prenatal 25(OH)D levels, race, and subsequent asthma
 or recurrent wheeze in offspring: Secondary analyses from the Vitamin D Antenatal
- Asthma Reduction Trial. J Allergy Clin Immunol, 140, 1423-1429 e5.
- WORLD HEALTH ORGANIZATION 2016. WHO recommendations on antenatal care for a
 positive pregnancy experience. Geneva: World Health Organization.
- WU, L., KWAK-KIM, J., ZHANG, R., LI, Q., LU, F. T., ZHANG, Y., WANG, H. Y.,
 ZHONG, L. W. & LIU, Y. S. 2018. Vitamin D level affects IVF outcome partially
 mediated via Th/Tc cell ratio. *Am J Reprod Immunol*, 80, e13050.
- YUAN, Y., TAI, W., XU, P., FU, Z., WANG, X., LONG, W., GUO, X., JI, C., ZHANG, L.,
 ZHANG, Y. & WEN, J. 2019. Association of maternal serum 25-hydroxyvitamin D
 concentrations with risk of preeclampsia: a nested case-control study and meta-*J Matern Fetal Neonatal Med*, 1-10.
- ZAHRAN, A. M., ZHARAN, K. M. & HETTA, H. F. 2018. Significant correlation between
 regulatory T cells and vitamin D status in term and preterm labor. *J Reprod Immunol*,
 129, 15-22.

- ZHANG, Q., CHENG, Y., HE, M., LI, T., MA, Z. & CHENG, H. 2016. Effect of various
 doses of vitamin D supplementation on pregnant women with gestational diabetes
 mellitus: A randomized controlled trial. *Exp Ther Med*, 12, 1889-1895.
- 2HOU, S. S., TAO, Y. H., HUANG, K., ZHU, B. B. & TAO, F. B. 2017. Vitamin D and risk
 of preterm birth: Up-to-date meta-analysis of randomized controlled trials and
 observational studies. *J Obstet Gynaecol Res*, 43, 247-256.

964

Table 1. Factors Affecting Clinical Outcomes of Vitamin D Supplementation Trials

967 during Pregnancy

•	Timing of intervention: when in gestation did supplementation occur
•	Sample size
•	Baseline serum 25(OH)D: e.g., the most profound effects
	of early supplementation seen in those with the lowest
	25(OH)D concentrations at baseline
٠	Sunshine exposure
•	Habitual vitamin D and calcium intake
•	Race/ethnicity
•	VDBP genotype
•	Dosing frequency of vitamin D: daily vs. weekly vs.
	monthly dosing
•	Adherence to dosing regimen
•	Types of assays used to measure 25(OH)D concentration
•	Type of analysis—Intention-to-treat vs. per protocol
•	Biomarker used for vitamin D status: Is total circulating
	25(OH)D concentration really the biomarker of what is
	going on at the cellular level during pregnancy? Should
	free 25(OH)D be measured? This is a question that
	comes up frequently.


973 Table 2. Characteristics and primary findings of five randomized controlled trials of
 974 prenatal vitamin D supplementation*

Country	Hollis 2011(Holl is et al., 2011) USA	Litonjua 2016 (VDAART)(Lito njua et al., 2016) USA	Cooper 2016 (MAVID OS) (Cooper et al., 2016) UK	Chawes 2016 (COPSAC)(Ch awes et al., 2016) Denmark	Roth 2018 (MDIG)(R oth et al., 2018b) Bangladesh	
Total N randomiz ed	502	881	1134	623	1300	
Highest vitamin D dose	4000 IU/day	4400 IU/day	1000 IU/day	2800 IU/day	4000 IU/day (given as 28,000 IU/week)	
Control group vitamin D dose	400 IU/day	400 IU/day	Placebo	400 IU/day	Placebo	
Primary outcome measure	Serum 25(OH)D concentrat ion	Early-childhood asthma or recurrent wheeze	Neonatal bone mass	Early-childhood persistent wheeze	Infant length (at one year of age)	
Effect of vitamin D on primary outcome	Strong positive effect	No significant effect	No significant effect	No significant effect	No significant effect	

975

976 *Trials selected if they were double-blind and enrolled >500 participants.

977



1,25(OH)₂D = 291.23 * (1-exp (-0.0243 * 25(OH)D))

980

981 Figure 1. Substrate-Product Relationships of Vitamin D Metabolites during Pregnancy.


982 This panel demonstrates the relationship circulating 25(OH)D to control the production of

983 1,25(OH)2D during pregnancy. All data points for all subjects in all groups were included in984 this analysis.

985 (from Hollis et al, 2011, Figure 3b Panel b, with permission (Hollis, 2011))



988



- 989
- 990
- 991

992 Figure 2. Schematic representation of the advantages and disadvantages of approaches 993 available to investigators when analyzing data from a randomized controlled trial. The 994 horizontal axis reflects the spectrum of choices related to the participant selection criteria. For 995 example, a discrete sub-group analysis may involve restriction to participants with baseline 996 25(OH)D<30 nmol/L, whereas population-representative sampling would include all 997 participants irrespective of baseline characteristics, adherence, or other non-random factors. 998 The vertical axis reflects the spectrum of choices related to the assignment of the exposure 999 variable. An intention-to-treat approach entails direct comparisons of the experimental versus 1000 control groups, relying only on the random assignment regardless of adherence or 1001 completeness of follow-up; in contrast, observational analyses usually ignore the random 1002 allocation and instead examine the association between an outcome and a non-random 1003 indicator of vitamin D status (e.g., 25(OH)D or number of vitamin D doses received). 1004